Welcome to our dedicated page for Tvardi Therapeutics SEC filings (Ticker: TVRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tvardi Therapeutics, Inc. (NASDAQ: TVRD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tvardi’s filings describe it as a Delaware corporation and a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Through documents such as Form 8-K current reports, investors can review Tvardi’s announcements regarding financial results, business updates, executive and director changes, compensation arrangements, and key clinical and corporate events. Recent 8-K filings have covered quarterly results, updates on preliminary data from the REVERT IPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, the availability of updated corporate presentations, and the adoption of a severance and change in control plan and retention equity awards for certain employees.
Registration statements on Form S-1/A offer additional detail on Tvardi’s business following its merger with Legacy Tvardi, the change of name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc., and the commencement of trading on The Nasdaq Capital Market under the symbol TVRD. These filings also outline the company’s status as a smaller reporting company and its focus on STAT3-targeted clinical programs, including TTI-101 and TTI-109.
On Stock Titan, Tvardi’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the key points in lengthy filings such as registration statements and current reports. Users can quickly identify items related to clinical trial disclosures, capital structure, compensation plans, and other material events, and can also monitor how Tvardi describes the progress and risks associated with its STAT3 inhibitor programs over time.
Tvardi Therapeutics, Inc. filed a prospectus supplement to increase its existing at-the-market offering program, permitting the issuance of up to $9,689,765 in additional shares of common stock under its Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC.
The shares are issued under an effective shelf registration statement on Form S-3 registering up to $12.5 million of common stock. The company is subject to General Instruction I.B.6 of Form S-3, the baby shelf rule, and reports an aggregate market value of non-affiliate common stock of $62,208,945, based on 12,441,789 non-affiliate shares at $5.00 per share. Over the prior twelve-month period, it sold 3,110,769 shares for approximately $11.0 million in gross proceeds under the earlier sales agreement prospectus, and no additional stock will be sold under that earlier prospectus.
Tvardi Therapeutics, Inc. is launching an at-the-market equity program to sell up to $9,689,765 of common stock through JonesTrading under an existing Capital on Demand Sales Agreement. JonesTrading will act as sales agent on a commercially reasonable efforts basis and receive up to 3.0% of gross proceeds as commission.
The company’s non‑affiliate float is valued at $62,208,945 under General Instruction I.B.6 of Form S‑3, and it has sold about $11.0 million of stock in the prior twelve months under this rule. Assuming sales at $3.08 per share, up to 3,146,027 new shares could be issued, increasing shares outstanding from a pro forma 12,492,113 to up to 15,638,140 and causing an illustrated dilution of $0.91 per share. Net proceeds are intended for general corporate purposes, including clinical trial, research and development, general and administrative expenses, capital expenditures and potential in‑licensing or acquisitions.
Tvardi Therapeutics reported Phase 1 results for TTI-109, an oral phosphate prodrug of its STAT3 inhibitor TTI-101, showing it rapidly converts to TTI-101 and achieves dose-proportional exposures above the STAT3 IC₅₀ in healthy volunteers.
Across single and multiple ascending dose cohorts, TTI-109 delivered TTI-101-equivalent systemic exposure at molar-equivalent doses and showed an improved gastrointestinal tolerability profile, with diarrhea rates and duration closer to placebo than TTI-101. Exploratory pharmacodynamic analyses found reductions of up to 60% in STAT3-driven immune cell populations, including Th17, T follicular helper and B cells, which are implicated in inflammatory and proliferative dermatologic and gastrointestinal diseases. Tvardi plans to advance TTI-109 into Phase 2 trials in these indications, subject to IND clearance and additional funding, while continuing its Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 in hepatocellular carcinoma and targeting topline data in the second half of 2026.
Tvardi Therapeutics, Inc. director Susan Shiff, Ph.D. received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.78 per share and expire on June 8, 2036. 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, subject to her continuous service. Following this grant, she holds 6,000 stock options directly.
Tvardi Therapeutics, Inc. director Cynthia Smith reported receiving a grant of stock options as equity compensation. The award covers 6,000 options to buy Tvardi common stock at an exercise price of $2.78 per share, expiring on June 8, 2036.
All 6,000 underlying shares vest in a single tranche on the earlier of June 9, 2027 or the date of Tvardi’s next annual meeting of stockholders, provided she remains in continuous service through that vesting date. Following this grant, she holds 6,000 derivative securities directly.
Tvardi Therapeutics director Sujal Shah received a stock option grant for 6,000 shares of common stock. The option has an exercise price of $2.78 per share and expires on June 8, 2036. All 6,000 underlying shares will vest on the earlier of June 9, 2027 or the company’s next annual stockholder meeting, assuming he remains in continuous service.
Tvardi Therapeutics, Inc. director Hall Wallace Jr. received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.78 per share and expire on June 8, 2036.
All 6,000 underlying shares will vest on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, as long as Wallace continues in service through that date. This is a compensation-related award rather than an open-market purchase or sale.
Tvardi Therapeutics, Inc. director Michael S. Wyzga received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.7800 per share and expire on June 8, 2036. Following this grant, he holds 6,000 derivative securities directly.
According to the terms, 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the date of Tvardi’s next annual meeting of stockholders, provided he continues serving through the vesting date. This is a compensation-related award rather than an open-market purchase.
Tvardi Therapeutics, Inc. reported the voting results from its Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah as Class II directors to serve until the 2029 annual meeting.
They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and indicated a preference for holding this advisory vote every year. In addition, stockholders ratified the Audit Committee’s selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.